Selank FAQ: 30 Questions from the Research Literature, Answered

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, MW 751.9 Da) derived from the immunomodulatory tetrapeptide tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is studied as an anxiolytic and nootropic agent. Registered in Russia as a prescription nasal spray in 2009. Not approved by the FDA or EMA.

In preclinical models Selank modulates GABA-A receptor sensitivity via indirect allosteric interaction, inhibits enkephalin-degrading peptidases (IC50 approximately 15–20 micromolar in plasma),^[3] upregulates hippocampal BDNF expression,^[2] and attenuates HPA-axis hyperactivity under stress.^[15] These converging pathways produce anxiolytic and mild cognitive-enhancing effects without the direct receptor binding associated with benzodiazepines.

Selank is primarily studied as an anxiolytic via GABAergic and enkephalin pathways. Semax is primarily studied for neuroprotection and cognitive enhancement via BDNF and ACTH-related pathways. The 2020 fMRI study demonstrated distinct brain connectivity signatures for each compound in healthy humans.^[20] They act through different primary pathways; the question of which is better depends entirely on the research domain. See Selank vs Semax comparison for the full comparison.

Preclinical protocols and the published Russian clinical trial used daily administration for 5–14 day courses. The human GAD trial ran 14 consecutive days at 2,700 micrograms per day intranasal.^[5] Chronic daily use data beyond 14 days in humans is limited — no systematic long-term safety or efficacy data for extended human use is available in the published record.

In the human fMRI study, functional connectivity changes were measurable at 5 minutes post-intranasal administration.^[20] In rodent models, behavioral effects appear within the first hour post-dose. The Russian GAD trial used a 14-day cumulative protocol; per-session onset was not reported separately. CNS access via the olfactory pathway after intranasal delivery is rapid — plasma clearance of the intact peptide begins within minutes.

Preclinical toxicity studies and the published Russian clinical trials (N=62) report a favorable safety profile with no significant organ toxicity at study doses.^[5] Occasional mild nasal irritation with intranasal administration is noted in clinical data. Long-term human safety data is absent; the evidence base is limited to a single 62-patient trial and Russian preclinical toxicology. Research-compound classification outside Russia applies.

Clinical trial subjects in the Russian GAD study reported reduced tension and improved mood on Hamilton and Zung scales; antiasthenic and psychostimulant effects were noted beyond anxiety reduction.^[5] Animal models show reduced anxiety behavior without sedation. Subjective experiential data in healthy humans is limited to the fMRI study measuring connectivity rather than self-reported affect.

The fMRI functional connectivity research (Panikratova et al. 2020, N=52) examined their combined and individual effects in healthy adults.^[20] Peer-reviewed combination safety and efficacy data is limited to that neuroimaging study — it does not report adverse events from combined administration. Combined injection protocols are used in some research contexts but have not been subjected to independent safety trials in the published literature.

Selank is tuftsin-derived (Thr-Lys-Pro-Arg core), primarily anxiolytic via GABA-A allosteric modulation and enkephalinase inhibition. Semax is ACTH4-7-derived, primarily studied for neuroprotection, BDNF upregulation, and cognitive enhancement. Semax inhibits enkephalinase at IC50 of 10 micromolar vs Selank's 20 micromolar.^[17] Their fMRI functional connectivity signatures in humans are distinct.^[20] See Selank vs Semax comparison.

Benzodiazepines bind directly to the GABA-A receptor benzodiazepine site. Selank is proposed to modulate GABA-A sensitivity indirectly and also inhibits enkephalin degradation.^[3][4] No direct binding to the benzodiazepine site has been demonstrated for Selank. Preclinical data shows no tolerance or withdrawal phenomena with Selank — consistent with the indirect mechanism. The combination of Selank and diazepam was additive in a chronic stress rat model.^[6]

Published preclinical and limited clinical data show no observed withdrawal syndrome or tolerance in published studies. The indirect GABAergic mechanism — without direct benzodiazepine-site binding — is proposed to underlie lower dependence potential. However, human long-term data is insufficient to characterize dependence risk fully. See Selank withdrawal research for the complete tolerance and dependence literature.

Intranasal delivery is used in the published Russian clinical trials and provides direct olfactory-nerve CNS access, bypassing first-pass hepatic metabolism.^[5][20] A 2016 route-comparison study found divergent receptor outcomes by route at the same dose — intranasal increased NMDA binding; intraperitoneal increased GABA-A binding.^[7] Comparative human bioavailability data has not been published.

N-Acetyl Selank Amidate combines N-terminal acetylation and C-terminal amidation — modifications proposed to increase resistance to enzymatic degradation and potentially extend in vivo half-life versus unmodified Selank. They are structurally distinct compounds. Independent comparative pharmacokinetic or efficacy studies in peer-reviewed literature are limited; treating them as equivalent in potency or duration is not supported by published data.

Plasma half-life is approximately 3–5 minutes due to rapid enzymatic cleavage by plasma peptidases. Behavioral effects in rodent models and human fMRI data^[20] persist well beyond this window, likely due to active metabolite formation — Selank's in vivo metabolites have been shown to retain biological activity^[19] — and downstream receptor-level kinetics that outlast the parent compound's plasma presence.

One published Russian RCT (Zozulia et al. 2008, N=62) found Selank equivalent to medazepam on Hamilton Anxiety Scale, Zung Scale, and Clinical Global Impression reductions over 14 days, with additional antiasthenic effects.^[5] Study limitations include single-trial evidence base, Russian-specific population, and lack of Western regulatory registration. No independent replication has been published.

Intranasal Selank in Wistar rats increased hippocampal BDNF mRNA and protein, measured by RT-PCR and immunoenzyme assay.^[2] In chronic ethanol exposure models, Selank preserved cognitive performance by normalizing BDNF in hippocampus and prefrontal cortex.^[8] The BDNF-TrkB pathway is proposed as a mechanism for both stress-resilience and nootropic effects. Human BDNF data from Selank administration is not available in indexed publications.

No dedicated PTSD human RCT has been published. Preclinical fear-extinction models show Selank reduces conditioned fear responses — a proposed basis for future investigation in trauma-related anxiety. The fMRI amygdala-temporal connectivity data^[20] provides indirect human neuroimaging support for effects on threat-processing circuits, but does not constitute clinical evidence for PTSD efficacy.

Selank is structurally derived from tuftsin, a known immunomodulatory tetrapeptide. In patients with anxiety-asthenic disorders, a 14-day Selank course altered Th1/Th2 cytokine balance and at 10^-7 M in vitro completely suppressed IL-6 gene expression in peripheral blood cells from depressed patients — not in healthy controls.^[12] Selank and its metabolites also demonstrated antiulcerogenic properties in rat gastric models.^[19]

At 300 micrograms per kilogram, Selank enhanced learning in active avoidance conditioning in rats, with effects appearing on the first training day and accumulating across four sessions.^[11] In initially poor learners, improvement was marked. Separately, Selank prevented ethanol-induced memory and attention deficits over 30 weeks of chronic alcohol exposure.^[8] Proposed mechanisms include BDNF upregulation and anxiety-reduction releasing working memory from stress interference.

Selank inhibits enkephalin-degrading peptidases dose-dependently with an IC50 of approximately 15 micromolar in human plasma^[3] — more potent than bacitracin and puromycin. In GAD patients, shortened enkephalin half-life was corrected by Selank treatment, with clinical response correlating with the biochemical change.^[5] Enkephalin prolongation is proposed to contribute to anxiolytic and mood-stabilizing effects by maintaining endogenous opioid tone.

Published preclinical and limited clinical data report minimal adverse events. Occasional mild nasal irritation with intranasal administration is noted. No significant cardiovascular, hepatic, or renal toxicity has been documented at study doses.^[5] The restraint-stress studies at 100–1,000 micrograms per kilogram reported protective hepatocyte effects.^[16] Systematic long-term human adverse event surveillance data is absent from the published record.

Selank was registered in Russia as an anxiolytic and nootropic prescription nasal spray in 2009 (registration certificate LS-000574). It is not approved by the FDA or EMA and is classified as a research compound outside Russia. No Phase 2 or Phase 3 submissions to Western regulatory agencies are documented in publicly indexed databases.

Selank is a synthetic heptapeptide analogue of tuftsin (Thr-Lys-Pro-Arg), the naturally occurring tetrapeptide fragment of IgG heavy chain with established immunomodulatory properties. The Pro-Gly-Pro extension was added to improve metabolic stability — tuftsin's plasma half-life is seconds; Selank's is approximately 3–5 minutes. The extension also confers neurological activity absent in the parent: Selank enhanced brainstem serotonin metabolism in a model where tuftsin had no effect.^[13] See Selank tuftsin origin.

A 2022 study (Konstantinopolsky et al., PMID 36322304) found Selank at 0.3 mg/kg intraperitoneal reduced the total morphine withdrawal syndrome index by 39.6% in naloxone-precipitated withdrawal in rats — with a nine-fold increase in tactile sensitivity threshold and significant reduction in convulsions, ptosis, and posture disorders.^[9] The proposed mechanism is enkephalinase inhibition. No human opioid-withdrawal data exists in the published record. See Selank withdrawal research.

Selank increased brainstem serotonin (5-HT) metabolism 30 minutes post-injection in PCPA-pretreated rats; tuftsin had no effect under the same conditions, distinguishing Selank's serotonergic profile.^[13] At high doses (1,000–2,000 micrograms per kilogram) in genetically depressed WAG/Rij rats, Selank activated brain monoaminergic systems including dopaminergic pathways, alongside antidepressant-like effects.^[14] Striatal dopamine modulation has been reported in neurochemical studies.

The primary published human trial included neurasthenia patients alongside GAD patients. Selank produced antiasthenic (anti-fatigue) and psychostimulant effects — improvements in fatigue, irritability, and concentration — not observed with the medazepam comparator.^[5] These effects are consistent with the BDNF upregulation and serotonin metabolism data from preclinical models and distinguish Selank's clinical profile from pure benzodiazepine anxiolytics.

Selank is proposed to enhance GABA-A receptor sensitivity via indirect allosteric modulation rather than direct binding to the benzodiazepine site. Gene expression studies show 45 GABAergic pathway genes altered at one hour post-dose;^[4] neuroblastoma cell studies show Selank suppresses GABA-induced gene expression changes when co-applied — a modulatory, not agonist, profile.^[18] No direct GABA-A binding site for Selank has been identified in the published structure-activity literature.

Selank at 80, 250, and 750 micrograms per kilogram intraperitoneal in chronically restrained Wistar rats decreased corticosterone levels and reduced pathomorphological stress manifestations in the colon — tissue atrophy, inflammatory response, and mast cell dysfunction — while accelerating stress adaptation.^[15] The hepatoprotective study at 100–1,000 micrograms per kilogram also reported protective effects on stress-induced hepatocyte oxidative damage.^[16] HPA axis normalization is one of the seven converging proposed mechanisms.

Published bioavailability percentages for intranasal Selank in humans are not available. CNS penetration is inferred from behavioral outcomes in preclinical models, the human fMRI data showing connectivity changes at 5 minutes post-dose,^[20] and the clinical trial response. Intranasal delivery via olfactory epithelium bypasses first-pass hepatic metabolism. Human Cmax, Tmax, and bioavailability fraction data are absent from the indexed literature.

In published research and the clinical literature, Semax is associated with focus, memory, and neuroprotection via BDNF and ACTH-related pathways. Selank is associated with anxiety reduction and stress resilience via GABAergic modulation and enkephalin pathways. Their fMRI connectivity signatures in humans are distinct.^[20] Semax inhibits enkephalinase at IC50 of 10 micromolar; Selank at 20 micromolar^[17] — both active, different potency. For full comparison, see Selank vs Semax comparison.